Creon 20

Drug Description
font size

CREON® 20
MINIMICROSPHERES®
(pancrelipase) Delayed-release Capsules, USP

DRUG DESCRIPTION

CREON® 20 Capsules are orally administered and contain pancrelipase (lipase 20,000 USP Units, protease 75,000 USP Units and amylase 66,400 USP Units per capsule) which is of porcine pancreatic origin. Each CREON 20 Capsule is filled with 497 mg of delayed-release MINIMICROSPHERES®.

Inactive ingredients include dibutyl phthalate, dimethicone, hydroxypropylmethylcellulose phthalate, light mineral oil and polyethylene glycol. The capsule shells contain gelatin, red iron oxide, titanium dioxide and yellow iron oxide. The capsule imprinting ink contains dimethicone, 2-ethoxyethanol, shellac, soya lecithin, and titanium dioxide.

Last updated on RxList: 9/29/2008

Creon 20 User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Creon 20 sorted by most helpful. Patient Discussions FAQs


Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Bookmark this page:


Women's Health

Find out what women really need.